Pfizer Inc and GlaxoSmithKline plc today announced they have entered into an agreement to create a premier global consumer healthcare company with robust iconic brands. The Boards of Directors of both companies have unanimously approved the transaction under which Pfizer will contribute its consumer healthcare business to GlaxoSmithKline’s existing consumer healthcare business. The 2017 global sales for the combined business were approximately $12.7 billion.

— Businesswire

L&L Partners advised GSK led by a team of partner William Vivian John Other team members managing associate Deepak Kumar, senior associate Rishabh Shah and associate Gayatri Loomba.

Update 12 June 2019: Khaitan & Co acted for Pfizer Inc on competition approvals, with executive director Paku Khan, partner Anisha Chand, senior associate Radhika Seth, associate Anmol Awasthi.

AZB & Partners advised GSK on competition laws, led by partner Samir Gandhi, with senior associates Rahul Satyan and Nikita Agarwal, and associates Nitin Nair, Ravi Gangal, Shreya Singh, Rajshree Sharma and Karan Sood.

Primary jurisdiction of deal: US, Global.

2018-12-19

Deal value: USD 650 million

{incomplete}